

## Media Release

7 June 2017

---

### PHARMAXIS APPOINTS FORMER HEAD OF GLOBAL RESEARCH AT MERCK TO BOARD OF DIRECTORS

---

Pharmaceutical research company Pharmaxis (ASX: PXS) today announced it has appointed Dr Kathleen Metters to the Board of Directors. Dr Metters has more than 25 years of experience in the discovery and development of novel therapies for the treatment of serious diseases.

Dr Metters spent 9 years as a senior executive with Merck & Co. (Merck Sharp & Dohme (MSD) outside the United States and Canada) which included a 4 year period as senior vice president and head of Worldwide Basic Research. That was followed by an appointment to design and establish External Discovery and Preclinical Sciences, created to expand Merck's scientific network to the greater research community in academia, biotechnology, and government; building partnerships in life sciences, medicine, engineering, and information technology.

After leaving Merck in 2011 Dr Metters was appointed President and Chief Executive Officer for Lycera Corp., a biopharmaceutical company pioneering innovative approaches to novel oral medicines for treatment of autoimmune diseases and cancer. Under her leadership, Lycera developed a robust pipeline of proprietary and partnered immune modulator programs which formed the basis, in June 2015, of an exclusive global collaboration with Celgene Corporation.

Dr Metters will serve as a Non Executive Director on the Pharmaxis Board – joining current members Malcolm McComas, Simon Buckingham, Will Delaat and Gary Phillips.

Pharmaxis Chairman Malcolm McComas said, "The appointment of Dr Metters to the Pharmaxis Board follows a global search for a candidate who could contribute to the Pharmaxis business model of creating value through excellence in drug discovery and development. Her distinguished career in drug discovery inside a major multinational Pharma company and more recent role as a CEO of a smaller biotech company gives Dr Metters the experience and insight to make a significant contribution to Pharmaxis. We are delighted to welcome her to the Board at a time when we are making significant steps forward with our pipeline of anti-inflammatory and anti-fibrotic therapies and progressing our aim to building a globally competitive company."

Dr Metters graduated with a B.S. in biochemistry from the University of Manchester Institute for Science and Technology, and a Ph.D. from Imperial College of Science and Technology in London. She completed post-doctoral training at the Centre National de la Recherche Scientifique in France and at the Clinical Research Institute of Montréal. She maintained her academic interests during her time in Montréal through an Adjunct Professor appointment in the Department of Pharmacology and Therapeutics at McGill University.

She is currently an independent biopharma consultant and as senior advisor for Bridge Medicines where she is working to improve the translation and commercialisation of research in New York based academic institutions.

#ends#

**SOURCE:** Pharmaxis Ltd, Sydney, Australia

**CONTACT:** Felicity Moffatt, phone +61 418 677 701 or email [felicity.moffatt@pharmaxis.com.au](mailto:felicity.moffatt@pharmaxis.com.au)

### **About Pharmaxis**

Pharmaxis (ACN 082 811 630) is an Australian research pharmaceutical company focused on inflammation and fibrosis with a portfolio of products at various stages of development and approval. Its product Bronchitol® for cystic fibrosis is marketed in Europe, Russia and Australia. Its product Aridol® for the assessment of asthma is sold in Europe, Australia and Asia. The company's development pipeline is centred on its expertise in amine oxidase chemistry and includes a series of Lysyl Oxidase Inhibitors that will enter clinical development in 2017 targeting fibrotic diseases of the heart, kidney, liver and lung. In May 2015, Boehringer Ingelheim acquired the Pharmaxis investigational drug PXS-4728A, a potent inhibitor of Semicarbazide-Sensitive Amine Oxidase (SSAO), to develop it for the treatment of the liver-related condition Non-alcoholic Steatohepatitis (NASH) and other inflammatory diseases. Pharmaxis is listed on the Australian Securities Exchange (symbol PXS). The company's head office, manufacturing and research facilities are located in Sydney, Australia. For more information about Pharmaxis, please see [www.pharmaxis.com.au](http://www.pharmaxis.com.au)

### **Forward-Looking Statements**

Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential of products and drug candidates. All forward-looking statements included in this media release are based upon information available to us as of the date hereof. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. These forward-looking statements are not guarantees or predictions of future results, levels of performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this document. Except as required by law we undertake no obligation to update these forward-looking statements as a result of new information, future events or otherwise.